Specifically, according to FORWARDII study, mirvetuximab Soravtansine combined with bevacizumab achieved an ORR of 44% and 48% in the PROC and PSOC populations, respectively, and a median PFS of 8.2 and 9.6 months, respectively, and regardless of the high, medium or low expression of FRα, combined treatments can show great benefit, showing stronger anti-tumor activity than a single drug, while maintaining a controllable safety profile [20, 22]. Here, FOLR1 is linked to neoplasm.